Research Paper Volume 13, Issue 6 pp 8643—8664

Follistatin-like protein 1 functions as a potential target of gene therapy in proliferative diabetic retinopathy

Stronger FSTL1 staining and weaker VEGF staining in the IVB-treated membranes. (A) FSTL1 and VEGF proliferative membrane immunofluorescence results in PDR patients with and without anti-VEGF treatment. Vimentin, as an internal reference. DAPI, the tracer shows the nuclear position of the fluorescent agent 4',6-diamidino-2-phenylindole (magnification: ×10). (B) The levels of FSTL1 and VEGF were analyzed using ImageJ. Stronger FSTL1 staining was detected in the IVB-treated membranes than in the untreated membranes, and VEGF staining was weaker in the IVB-treated group than in the untreated group. Data are expressed as mean ± SEM. * means P

Figure 6. Stronger FSTL1 staining and weaker VEGF staining in the IVB-treated membranes. (A) FSTL1 and VEGF proliferative membrane immunofluorescence results in PDR patients with and without anti-VEGF treatment. Vimentin, as an internal reference. DAPI, the tracer shows the nuclear position of the fluorescent agent 4',6-diamidino-2-phenylindole (magnification: ×10). (B) The levels of FSTL1 and VEGF were analyzed using ImageJ. Stronger FSTL1 staining was detected in the IVB-treated membranes than in the untreated membranes, and VEGF staining was weaker in the IVB-treated group than in the untreated group. Data are expressed as mean ± SEM. * means P < 0.05, **means P < 0.01, *** means P < 0.001.